BingLiang Ph.D.

Associate

(T) + 1.650.687.4168

Dr. Bing Liang represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property. Her practice encompasses global patent portfolio development, management, and enforcement, particularly in the areas of biologics and diagnostics.

She prepares and prosecutes patent applications in a variety of technologies including antibody therapeutics, immuno-oncology therapeutics, cell therapies, genome editing, antisense therapeutics, enzyme replacement therapies, stem cells, and whole genome sequencing.

Bing advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals. She is experienced in licensing agreements and matters related to FDA approval.

Her practice also includes various post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), including inter partes reviews (IPRs).

Her representative clients include AbbVie, BioMarin Pharmaceutical, Celgene, and Genentech, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to practicing law, Bing obtained her Ph.D. in biomedical sciences from Mount Sinai School of Medicine of New York University, where her research focused on chromatin remodeling and its functions in maintaining genome integrity. During this time she discovered important roles of chromatin remodeling complexes in DNA damage repair and telomere length maintenance. Bing has extensive technical experience in biochemistry, molecular biology, genetics, immunology, and cell biology.

Experience

  • Celgene to be acquired by Bristol-Myers Squibb for approx. $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • NGM develops global patent portfolio for beta-klotho antibodiesJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.
  • Scynexis launches public offering of Common StockJones Day led a team that handled the IP diligence for a follow-on public offering of common stock for Scynexis, Inc., a Research Triangle Park, North Carolina, pharmaceutical company committed to the discovery, development, and commercialization of novel anti-infectives.
  • Perlan establishes global patent portfolio for ICAM1 antibodiesJones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.
  • BioMarin establishes global patent portfolio for PAL technologyOn behalf of BioMarin Pharmaceutical, Inc., Jones Day assisted with global patent portfolio development and prosecution strategies regarding Prokaryotic Phenylalanine Ammonia-Lyase (PAL).
  • Speaking Engagements

    • April 20, 2019
      The Life Science Patent Landscape and Capital Markets - Updates in China and US, 2019 Chinese Bioscience Association Symposium
    • October 14, 2017
      Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference
    • May 8, 2015
      Lecture Presentation, Beijing Foreign Studies University, "Patent Operation in Biotechnological and Pharmaceutical Industries."
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.